Single-Fraction vs Multifraction Radiotherapy and Ambulatory Status in Patients With Spinal Canal Compression | Neurology | JN Learning | AMA Ed Hub [Skip to Content]
[Skip to Content Landing]

Effect of Single-Fraction vs Multifraction Radiotherapy on Ambulatory Status Among Patients With Spinal Canal Compression From Metastatic CancerThe SCORAD Randomized Clinical Trial

Educational Objective
To understand the effect of single-dose radiotherapy vs multifraction radiotherapy for managing spinal canal compression in patients with metastatic cancer.
1 Credit CME
Key Points

Question  Is treatment with a single dose of radiotherapy noninferior to multifraction radiotherapy delivered over 5 days among patients with metastatic cancer who have spinal canal compression?

Findings  In a clinical trial of 686 patients, the percentage who were ambulatory at 8 weeks was 69.3% in the single-fraction group vs 72.7% in the multifraction radiotherapy group. The lower CI limit for the risk difference (−11.5%) did not meet the predefined noninferiority margin of −11.0%.

Meaning  Treatment with single-fraction radiotherapy did not meet the criterion for noninferiority compared with multifraction radiotherapy for ambulatory response rate at 8 weeks, but consideration should be given to the extent to which the lower bound of the CI overlapped with the noninferiority margin.

Abstract

Importance  Malignant spinal canal compression, a major complication of metastatic cancer, is managed with radiotherapy to maintain mobility and relieve pain, although there is no standard radiotherapy regimen.

Objective  To evaluate whether single-fraction radiotherapy is noninferior to 5 fractions of radiotherapy.

Design, Setting, and Participants  Multicenter noninferiority randomized clinical trial conducted in 42 UK and 5 Australian radiotherapy centers. Eligible patients (n = 686) had metastatic cancer with spinal cord or cauda equina compression, life expectancy greater than 8 weeks, and no previous radiotherapy to the same area. Patients were recruited between February 2008 and April 2016, with final follow-up in September 2017.

Interventions  Patients were randomized to receive external beam single-fraction 8-Gy radiotherapy (n = 345) or 20 Gy of radiotherapy in 5 fractions over 5 consecutive days (n = 341).

Main Outcomes and Measures  The primary end point was ambulatory status at week 8, based on a 4-point scale and classified as grade 1 (ambulatory without the use of aids and grade 5 of 5 muscle power) or grade 2 (ambulatory using aids or grade 4 of 5 muscle power). The noninferiority margin for the difference in ambulatory status was −11%. Secondary end points included ambulatory status at weeks 1, 4, and 12 and overall survival.

Results  Among 686 randomized patients (median [interquartile range] age, 70 [64-77] years; 503 (73%) men; 44% had prostate cancer, 19% had lung cancer, and 12% had breast cancer), 342 (49.8%) were analyzed for the primary end point (255 patients died before the 8-week assessment). Ambulatory status grade 1 or 2 at week 8 was achieved by 115 of 166 (69.3%) patients in the single-fraction group vs 128 of 176 (72.7%) in the multifraction group (difference, −3.5% [1-sided 95% CI, −11.5% to ∞]; P value for noninferiority = .06). The difference in ambulatory status grade 1 or 2 in the single-fraction vs multifraction group was −0.4% (63.9% vs 64.3%; [1-sided 95% CI, −6.9 to ∞]; P value for noninferiority = .004) at week 1, −0.7% (66.8% vs 67.6%; [1-sided 95% CI, −8.1 to ∞]; P value for noninferiority = .01) at week 4, and 4.1% (71.8% vs 67.7%; [1-sided 95% CI, −4.6 to ∞]; P value for noninferiority = .002) at week 12. Overall survival rates at 12 weeks were 50% in the single-fraction group vs 55% in the multifraction group (stratified hazard ratio, 1.02 [95% CI, 0.74-1.41]). Of the 11 other secondary end points that were analyzed, the between-group differences were not statistically significant or did not meet noninferiority criterion.

Conclusions and Relevance  Among patients with malignant metastatic solid tumors and spinal canal compression, a single radiotherapy dose, compared with a multifraction dose delivered over 5 days, did not meet the criterion for noninferiority for the primary outcome (ambulatory at 8 weeks). However, the extent to which the lower bound of the CI overlapped with the noninferiority margin should be considered when interpreting the clinical importance of this finding.

Trial Registration  ISRCTN Identifiers: ISRCTN97555949 and ISRCTN97108008

Sign in to take quiz and track your certificates

Buy This Activity

JN Learning™ is the home for CME and MOC from the JAMA Network. Search by specialty or US state and earn AMA PRA Category 1 CME Credit™ from articles, audio, Clinical Challenges and more. Learn more about CME/MOC

Article Information

Corresponding Author: Peter J. Hoskin, BSc, MBBS, MD, Mount Vernon Cancer Centre, Rickmansworth Road, Northwood HA6 2RN, United Kingdom (peterhoskin@nhs.net).

Accepted for Publication: October 9, 2019.

Author Contributions: Dr Hoskin and Mr Lopes had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr Hoskin and Mssrs Hackshaw and Lopes contributed equally to this article.

Concept and design: Dixit, Foran, Forsyth, Hackshaw, Hopkins, Hoskin, Lopes, Misra.

Acquisition, analysis, or interpretation of data: Arnott, Bates, Beare, Brown, Dubois, Foran, Forsyth, Hackshaw, Holt, Hopkins, Hoskin, Lester, Lopes, MacGregor, Madhavan, McKinna, McMenemin, Misra, O'Rourke, Reczko, Roos, Sevitt, Thomas.

Drafting of the manuscript: Beare, Foran, Forsyth, Hackshaw, Hoskin, Lopes, McMenemin, Misra, Reczko.

Critical revision of the manuscript for important intellectual content: Arnott, Bates, Brown, Dixit, Dubois, Foran, Hackshaw, Holt, Hopkins, Hoskin, Lester, Lopes, MacGregor, Madhavan, McKinna, McMenemin, Misra, O'Rourke, Roos, Sevitt, Thomas.

Statistical analysis: Hackshaw, Lopes.

Obtained funding: Hackshaw, Hoskin, Roos.

Administrative, technical, or material support: Arnott, Beare, Dixit, Foran, Forsyth, Hackshaw, Hoskin, Lester, MacGregor, Reczko, Thomas.

Supervision: Beare, Hackshaw, Hoskin, McKinna, Misra, O'Rourke.

Conflict of Interest Disclosures: Dr Hoskin reported being supported by the National Institute for Health Research Manchester Biomedical Research Centre. Dr Beare reported receiving grants from Cancer Research UK during the conduct of the study. Dr Foran reported receiving personal fees and nonfinancial support from Bristol-Myers Squibb and Merck outside the submitted work. Dr Hackshaw reported receiving grants from Cancer Research UK during the conduct of the study and support from the University College London and University College London Hospital Biomedical Research Centre. Mr Lopes reported receiving support from the University College London and University College London Hospital Biomedical Research Centre. Dr Misra is the clinical lead for Metastatic Spinal Cord Compression in Manchester, UK. Ms Reczko reported receiving grants from Cancer Research UK during the conduct of the study. Dr Roos reported receiving grants from the Cancer Council Queensland during the conduct of the study. No other disclosures were reported.

Funding/Support: The trial was sponsored by University College London (UCL/09/0199) and coordinated by the Cancer Research UK and UCL Cancer Trials Centre. The trial was funded by CRUK Project Grants C2422/7932 and C2422/A11408 (funder reference CRUK/06/034) and by the Cancer Council Queensland for Australian Site Data Management. UK trial centers were supported by the UK National Institute of Health Research.

Role of the Funder/Sponsor: The funders had no role in the design and conduct of the study; collection, management, analysis, and interpretation of the data; preparation, review, or approval of the manuscript; and decision to submit the manuscript for publication.

Data Sharing Statement: See Supplement 4.

Additional Contributions: We are indebted to the research teams in the 47 sites listed below that contributed to this study and to the patients and families of all the patients who participated. We are also grateful to the independent data monitoring committee (John Yarnold, FRCR [The Institute of Cancer Research, UK]; Patricia Price, FRCP [Imperial College London, UK]; Lucy Kilburn, MSc [The Institute of Cancer Research, UK]) and the trial steering committee (Nick Reed, MBBS [The Beatson West of Scotland Cancer Centre, UK]; Andrew Clamp, PhD [The Christie NHS Foundation Trust]; Fergus Macbeth, FRCR [Velindre Cancer Centre, UK]; Richard Stephens, [UCL MRC Clinical Trials Unit, UK]). None of these individuals received compensation for their work on SCORAD. Principal investigators: United Kingdom: Peter Hoskin, MD (Mount Vernon Hospital); Amarnath Challapalli, MD (Bristol Haematology and Oncology Centre); Rhona McMenemin (Freeman Hospital); Danny Dubois, MD (Queen Alexandra Hospital, Portsmouth); Fiona McKinna, MD (Royal Sussex County Hospital); Bernadette Foran, MD (Weston Park Hospital, Sheffield); Vivek Misra, MD (Christie Hospital); Krishnaswamy Madhavan, MD (Southend University Hospital); Carol MacGregor, MD (Raigmore Hospital); Andrew Bates, MD (Southampton General Hospital); Jason F. Lester, MD (Velindre Hospital); Noelle O'Rourke, MD (West of Scotland Beatson Cancer Centre); Tim Sevitt, MD (Kent Oncology Centre); Sanjay Dixit (Castle Hill Hospital); Natasha Mithal, MD (Kent and Canterbury Hospital); David Wilkinson, MD (James Cook University Hospital); Stephanie Gibbs, MD (Queen's Hospital, Romford); Mark Beresford, MD (Royal United Hospital); Sally Morgan, MD (Nottingham City Hospital); Conrad Lewanski, MD (Charing Cross Hospital); Nicola Cornelius, MD (Lincoln County Hospital); Tom Roques, MD (Norfolk and Norwich Hospital); Virginia Wolstenholme, MD (St Bartholomew's Hospital); Sam Guglani, MD (Cheltenham General Hospital); Mohini Varughese, MD (Musgrove Park Hospital); Sarah Treece, MD (Peterborough District Hospital); Helen O'Donnell, MD (Royal Berkshire Hospital); Delia Pudney, MD (Singleton Hospital); Ian Sayers, MD (New Cross Hospital); Maxine Flubacher, MD (Dorset Cancer Centre, Poole); Liz Toy, MD (Royal Devon and Exeter Hospital); Peter Bliss, MD (Torbay District General Hospital); Alison Franks, MD (University Hospital Coventry); Claire Esler, MD (Leicester Royal Infirmary); Dan Ford, MD (Queen Elizabeth Hospital, Birmingham); Rob Turner, MD (St James's University Hospital); Jonathan Nicoll, MD (Cumberland Infirmary); Geoffrey Coghill, MD (Derriford Hospital); Alan Lamont, MD (Essex County Hospital); Isabel Syndikus, MD (Clatterbridge Centre for Oncology); Simon Gollins, MD (North Wales Cancer Trials Centre); Prakash Ramachandra, MD (Russells Hall Hospital); Australia: Daniel Roos, MD (Royal Adelaide Hospital); Tanya Holt, MD (Mater Centre, Brisbane); Bryan Burmeister, MD (Princess Alexandra Hospital, Queensland); Amy Shorthouse, MD (Canberra Hospital); Patrick Dwyer, MD (Lismore Hospital).

References
1.
Metastatic spinal cord compression in adults: risk assessment, diagnosis and management. Manchester, UK: National Institute for Health and Clinical Excellence; 2008. https://www.nice.org.uk/guidance/cg75/resources/metastatic-spinal-cord-compression-in-adults-risk-assessment-diagnosis-and-management-pdf-975630102469. Published November 26, 2008. Accessed August 8, 2019.
2.
Schmidt  MH , Klimo  P  Jr , Vrionis  FD .  Metastatic spinal cord compression.   J Natl Compr Canc Netw. 2005;3(5):711-719. doi:10.6004/jnccn.2005.0041PubMedGoogle ScholarCrossref
3.
Loblaw  DA , Laperriere  NJ .  Emergency treatment of malignant extradural spinal cord compression: an evidence-based guideline.   J Clin Oncol. 1998;16(4):1613-1624. doi:10.1200/JCO.1998.16.4.1613PubMedGoogle ScholarCrossref
4.
Loblaw  DA , Perry  J , Chambers  A , Laperriere  NJ .  Systematic review of the diagnosis and management of malignant extradural spinal cord compression: the Cancer Care Ontario Practice Guidelines Initiative’s Neuro-Oncology Disease Site Group.   J Clin Oncol. 2005;23(9):2028-2037. doi:10.1200/JCO.2005.00.067PubMedGoogle ScholarCrossref
5.
Chow  E , Harris  K , Fan  G , Tsao  M , Sze  WM .  Palliative radiotherapy trials for bone metastases: a systematic review.   J Clin Oncol. 2007;25(11):1423-1436. doi:10.1200/JCO.2006.09.5281PubMedGoogle ScholarCrossref
6.
Chow  E , Zeng  L , Salvo  N , Dennis  K , Tsao  M , Lutz  S .  Update on the systematic review of palliative radiotherapy trials for bone metastases.   Clin Oncol (R Coll Radiol). 2012;24(2):112-124. doi:10.1016/j.clon.2011.11.004PubMedGoogle ScholarCrossref
7.
Qu  S , Meng  HL , Liang  ZG ,  et al.  Comparison of short-course radiotherapy versus long-course radiotherapy for treatment of metastatic spinal cord compression: a systematic review and meta-analysis.   Medicine (Baltimore). 2015;94(43):e1843. doi:10.1097/MD.0000000000001843PubMedGoogle Scholar
8.
Abu-Hegazy  M , Wahba  HA .  Single versus multi-fraction radiation treatment for metastatic spinal cord compression: functional outcome study.   Chinese-German J Clin Oncol. 2011;10:535-540. doi:10.1007/s10330-011-0832-5Google ScholarCrossref
9.
National Institute for Health and Care Excellence.  Metastatic Spinal Cord Compression in Adults: Risk Assessment, Diagnosis, and Management. Manchester, UK: National Collaborating Centre for Cancer; 2008. https://www.nice.org.uk/guidance/cg75/resources/metastatic-spinal-cord-compression-in-adults-risk-assessment-diagnosis-and-management-pdf-975630102469.
10.
Lutz  S , Balboni  T , Jones  J ,  et al.  Palliative radiation therapy for bone metastases: update of an ASTRO evidence-based guideline.   Pract Radiat Oncol. 2017;7(1):4-12. doi:10.1016/j.prro.2016.08.001PubMedGoogle ScholarCrossref
11.
National Comprehensive Cancer Network (NCCN) guidelines in oncology. Adult cancer pain. Version 1.2018. January 2018.
12.
Aids to the Examination of the Peripheral Nervous System: Memorandum No. 45. London, UK: Medical Research Council; 1976. https://mrc.ukri.org/documents/pdf/aids-to-the-examination-of-the-peripheral-nervous-system-mrc-memorandum-no-45-superseding-war-memorandum-no-7/. Accessed August 8, 2019.
13.
Aaronson  NK , Ahmedzai  S , Bergman  B ,  et al.  The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology.   J Natl Cancer Inst. 1993;85(5):365-376. doi:10.1093/jnci/85.5.365PubMedGoogle ScholarCrossref
14.
Lee  KA , Dunne  M , Small  C ,  et al.  (ICORG 05-03): prospective randomized non-inferiority phase III trial comparing two radiation schedules in malignant spinal cord compression (not proceeding with surgical decompression); the quality of life analysis.   Acta Oncol. 2018;57(7):965-972. doi:10.1080/0284186X.2018.1433320PubMedGoogle ScholarCrossref
15.
Thirion  P , O’Sullivan  L , Clayton-Lea  A ,  et al.  ICORG 05-03: prospective randomized non-inferiority phase 3 trial comparing two radiation schedules in malignant spinal cord compression not proceeding with surgical decompression.   Int J Radiat Oncol Biol Phys. 2014;90(5):1263-1264. doi:10.1016/j.ijrobp.2014.10.036Google ScholarCrossref
16.
Maranzano  E , Trippa  F , Casale  M ,  et al.  8Gy single-dose radiotherapy is effective in metastatic spinal cord compression: results of a phase III randomized multicentre Italian trial.   Radiother Oncol. 2009;93(2):174-179. doi:10.1016/j.radonc.2009.05.012PubMedGoogle ScholarCrossref
17.
Raghunathan  TE , Lepkowski  JM , Van Hoewyk  J , Solenberger  P .  A multivariate technique for multiply imputing missing values using a sequence of regression models.   Surv Methodol. 2001;27:85-95.Google Scholar
18.
StataCorp.  Stata 15 Multiple-imputation Manual. College Station, TX: Stata Press; 2017.
19.
McDonald  R , Ding  K , Brundage  M ,  et al.  Effect of radiotherapy on painful bone metastases: a secondary analysis of the NCIC Clinical Trials Group Symptom Control Trial SC.23.   JAMA Oncol. 2017;3(7):953-959. doi:10.1001/jamaoncol.2016.6770PubMedGoogle ScholarCrossref
20.
Cocks  K , King  MT , Velikova  G , Martyn St-James  M , Fayers  PM , Brown  JM .  Evidence-based guidelines for determination of sample size and interpretation of the European Organisation for the Research and Treatment of Cancer Quality of Life Questionnaire Core 30.   J Clin Oncol. 2011;29(1):89-96. doi:10.1200/JCO.2010.28.0107PubMedGoogle ScholarCrossref
21.
Maranzano  E , Bellavita  R , Rossi  R ,  et al.  Short-course versus split-course radiotherapy in metastatic spinal cord compression: results of a phase III, randomized, multicenter trial.   J Clin Oncol. 2005;23(15):3358-3365. doi:10.1200/JCO.2005.08.193PubMedGoogle ScholarCrossref
22.
van der Linden  YM , Steenland  E , van Houwelingen  HC ,  et al  Patients with a favourable prognosis are equally palliated with single and multiple fraction radiotherapy: results on survival in the Dutch bone metastasis study.   Radiother Oncol. 2006;78(3):245-253. doi:10.1016/j.radonc.2006.02.007PubMedGoogle ScholarCrossref
23.
Hartsell  WF , Scott  CB , Bruner  DW ,  et al  Randomized trial of short- versus long-course radiotherapy for palliation of painful bone metastases.   J Natl Cancer Inst. 2005;97(1):798-804. doi:10.1093/jnci/dji139PubMedGoogle ScholarCrossref
24.
Loblaw  DA , Mitera  G , Ford  M , Laperriere  NJA .  A 2011 updated systematic review and clinical practice guideline for the management of malignant extradural spinal cord compression.   Int J Radiat Oncol Biol Phys. 2012;84(2):312-317. doi:10.1016/j.ijrobp.2012.01.014PubMedGoogle ScholarCrossref
25.
Ryu  S , Maranzano  E , Schild  SE ,  et al.  International survey of the treatment of metastatic spinal cord compression.   J Radiosurg SBRT. 2015;3(3):237-245.PubMedGoogle Scholar
26.
Bekelman  JE , Epstein  AJ , Emanuel  EJ .  Single- vs multiple-fraction radiotherapy for bone metastases from prostate cancer.   JAMA. 2013;310(14):1501-1502. doi:10.1001/jama.2013.277081PubMedGoogle ScholarCrossref
27.
Borras  JM , Dunscombe  P , Barton  M ,  et al.  Assessing the gap between evidence based indications for radiotherapy and actual practice in European countries.   Value Health. 2015;18(7):A481-A482. doi:10.1016/j.jval.2015.09.1311Google ScholarCrossref
28.
Lievens  Y , Defourny  N , Coffey  M ,  et al; HERO Consortium.  Radiotherapy staffing in the European countries: final results from the ESTRO-HERO survey.   Radiother Oncol. 2014;112(2):178-186. doi:10.1016/j.radonc.2014.08.034PubMedGoogle ScholarCrossref
29.
Borras  JM , Lievens  Y , Dunscombe  P ,  et al.  The optimal utilization proportion of external beam radiotherapy in European countries: an ESTRO-HERO analysis.   Radiother Oncol. 2015;116(1):38-44. doi:10.1016/j.radonc.2015.04.018PubMedGoogle ScholarCrossref
30.
Oxford Cancer Intelligence Unit National Cancer Intelligence Network. Travel times and distances to radiotherapy centres for head and neck cancer patients in England (2006-2008). http://www.ncin.org.uk/cancer_type_and_topic_specific_work/cancer_type_specific_work/head_and_neck_cancers/head_and_neck_cancer_hub/resources. Published 2012. Accessed November 9, 2018.
31.
Lin  CC , Bruinooge  SS , Kirkwood  MK ,  et al.  Association between geographic access to cancer care and receipt of radiation therapy for rectal cancer.   Int J Radiat Oncol Biol Phys. 2016;94(4):719-728. doi:10.1016/j.ijrobp.2015.12.012PubMedGoogle ScholarCrossref
32.
Rades  D , Šegedin  B , Conde-Moreno  AJ ,  et al.  Radiotherapy With 4 Gy × 5 Versus 3 Gy × 10 for metastatic epidural spinal cord compression: final results of the SCORE-2 Trial (ARO 2009/01).   J Clin Oncol. 2016;34(6):597-602. doi:10.1200/JCO.2015.64.0862PubMedGoogle ScholarCrossref
33.
Rades  D , Conde-Moreno  AJ , Cacicedo  J ,  et al.  Comparison of two radiotherapy regimens for metastatic spinal cord compression: subgroup analyses from a randomized trial.   Anticancer Res. 2018;38(2):1009-1015.PubMedGoogle Scholar
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
If you are not a JN Learning subscriber, you can either:
Subscribe to JN Learning for one year
Buy this activity
jn-learning_Modal_Multimedia_LoginSubscribe_Purchase
Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close

Name Your Search

Save Search
Close
With a personal account, you can:
  • Track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
jn-learning_Modal_SaveSearch_NoAccess_Purchase
Close

Lookup An Activity

or

Close

My Saved Searches

You currently have no searches saved.

Close
With a personal account, you can:
  • Access free activities and track your credits
  • Personalize content alerts
  • Customize your interests
  • Fully personalize your learning experience
Education Center Collection Sign In Modal Right
Close